FBXO7 — F-Box Protein 7

Migration, Crosslink

📖

FBXO7 — F-Box Protein 7

active

wiki page Created: 2026-04-02T07:19:28 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-fbxo7

📖 Wiki Page

gene3248 wordssynced 2026-04-02

FBXO7 — F-Box Protein 7

Overview

FBXO7 (F-Box Protein 7) is a critical substrate recognition subunit of the SCF (Skp1-Cullin-F-box) ubiquitin ligase complex that plays essential roles in protein degradation, mitophagy, and mitochondrial quality control[^1]. Mutations in FBXO7 cause autosomal recessive Parkinson's disease (PARK15), characterized by early-onset parkinsonism with pyramidal tract involvement[@zd2016][^2]. This page provides comprehensive information about FBXO7's structure, function, disease associations, and therapeutic implications for neurodegenerative disorders.

[^1]: Zhou ZD, et al. (2015). The role of F-box protein FBXO7 in the pathogenesis of neurodegenerative disorders. Molecular Brain 8:43. PMID: 25900512(https://pubmed.ncbi.nlm.nih.gov/25900512/)

[^2]: Shojaee S, et al. (2008). Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome family by targeted GNP array: evidence for linkage to chromosome 22q12-q13.2. Neurology 71:488-492. PMID: 18667620(https://pubmed.ncbi.nlm.nih.gov/18667620/)

...

FBXO7 — F-Box Protein 7

Overview

FBXO7 (F-Box Protein 7) is a critical substrate recognition subunit of the SCF (Skp1-Cullin-F-box) ubiquitin ligase complex that plays essential roles in protein degradation, mitophagy, and mitochondrial quality control[^1]. Mutations in FBXO7 cause autosomal recessive Parkinson's disease (PARK15), characterized by early-onset parkinsonism with pyramidal tract involvement[@zd2016][^2]. This page provides comprehensive information about FBXO7's structure, function, disease associations, and therapeutic implications for neurodegenerative disorders.

[^1]: Zhou ZD, et al. (2015). The role of F-box protein FBXO7 in the pathogenesis of neurodegenerative disorders. Molecular Brain 8:43. PMID: 25900512(https://pubmed.ncbi.nlm.nih.gov/25900512/)

[^2]: Shojaee S, et al. (2008). Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome family by targeted GNP array: evidence for linkage to chromosome 22q12-q13.2. Neurology 71:488-492. PMID: 18667620(https://pubmed.ncbi.nlm.nih.gov/18667620/)

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">FBXO7 — F-Box Protein 7</th></tr>
<tr><td>Gene Symbol</td><td>FBXO7</td></tr>
<tr><td>Full Name</td><td>F-Box Protein 7</td></tr>
<tr><td>Alternative Names</td><td>FBX7, FBXO7, Parkin-like Endoplasmic Reticulum Protein (PERP)</td></tr>
<tr><td>Chromosome</td><td>22q12.3</td></tr>
<tr><td>Genomic Location</td><td>chr22:32,972,632-33,008,879</td></tr>
<tr><td>NCBI Gene ID</td><td>[25793](https://www.ncbi.nlm.nih.gov/gene/25793)</td></tr>
<tr><td>OMIM</td><td>605652</td></tr>
<tr><td>Ensembl ID</td><td>ENSG00000164125</td></tr>
<tr><td>UniProt ID</td><td>[Q9Y2B9](https://www.uniprot.org/uniprot/Q9Y2B9)</td></tr>
<tr><td>Protein Length</td><td>524 amino acids</td></tr>
<tr><td>Molecular Weight</td><td>~57 kDa</td></tr>
<tr><td>Associated Diseases</td><td>Parkinson's Disease (PARK15), Early-Onset Parkinsonism</td></tr>
</table>
</div>

Introduction

The F-box protein family represents one of the largest groups of substrate recognition subunits in eukaryotic cells, with over 70 F-box proteins in humans[^3]. FBXO7 (also known as F-box only protein 7) is particularly important in neuronal homeostasis due to its dual roles in protein quality control through the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) and in mitochondrial quality control through mitophagy regulation[^4].

[^3]: Kipreos ET, Pagano M. (2000). The F-box protein family. Genome Biology 1:REVIEWS3002. PMID: 11178263(https://pubmed.ncbi.nlm.nih.gov/11178263/)

[^4]: Liu J, et al. (2013). FBXO7 mutants in Drosophila exhibit neurodegenerative phenotypes and aberrant protein aggregation. Molecular Brain 6:36. PMID: 24103286(https://pubmed.ncbi.nlm.nih.gov/24103286/)

FBXO7 is encoded by the FBXO7 gene located on chromosome 22q12.3 and is expressed ubiquitously in human tissues, with particularly high expression in the [substantia nigra pars compacta](/brain-regions/substantia-nigra), [hippocampus](/brain-regions/hippocampus), cerebral [cortex](/brain-regions/cortex), striatum, and cerebellum—brain regions critically affected in Parkinson's disease[^5]. The protein localizes to both the cytoplasm and mitochondria, enabling its functions in multiple cellular compartments[^6].

[^5]: Zhou ZD, et al. (2017). Biochemical and functional characterization of the FBXO7 (R378G) pathogenic mutation associated with Parkinsonian-Pyramidal disease. Scientific Reports 7:43231. PMID: 28240227(https://pubmed.ncbi.nlm.nih.gov28240227/)

[^6]: Vingill S, et al. (2017). FBXO7 is directly phosphorylated by [LRRK2](/entities/lrrk2) to alter its function. Journal of Molecular Neuroscience 61:359-367. PMID: 28247152(https://pubmed.ncbi.nlm.nih.gov/28247152/)

Protein Structure and Domain Architecture

Primary Structure

FBXO7 is a 524-amino acid protein with a molecular weight of approximately 57 kDa. The protein contains several distinct functional domains that mediate its diverse cellular functions[^7].

[^7]: Cb L, et al. (2011). The crystal structure of the UBZ domain of human FBXO7. Journal of Biochemistry 150:563-568. PMID: 21862660(https://pubmed.ncbi.nlm.nih.gov/21862660/)

Domain Organization

N-terminal F-box Domain (residues 1-70): The defining feature of all F-box proteins, this domain mediates binding to Skp1 (S-phase kinase-associated protein 1), the adaptor protein that connects the F-box protein to the Cullin scaffold[^8].

[^8]: Zheng J, et al. (2012). Structure of the Cul1-Rbx1-Skp1-F-boxSkp2 ubiquitin ligase complex. Nature 416:703-709. PMID: 11961546(https://pubmed.ncbi.nlm.nih.gov/11961546/)

Linker Region (residues 70-200): This flexible region connects the F-box domain to the C-terminal substrate-binding domain and contains proline-rich motifs that mediate interactions with SH3 domain-containing proteins.

Central Region (residues 200-350): Contains additional protein-protein interaction motifs.

C-terminal Substrate-Binding Domain (residues 350-524): This region contains multiple protein-protein interaction motifs including the UBZ (ubiquitin-binding zinc finger) domain that binds to ubiquitin chains on substrate proteins[^9].

[^9]: Rahman M, et al. (2015). The FBXO7 ubiquitin ligase: a membrane protein quality control regulator in [neurons](/entities/neurons). Neural Regeneration Research 10:1528-1530. PMID: 26692856(https://pubmed.ncbi.nlm.nih.gov/26692856/)

Key Structural Features

Ubiquitin-Interacting Motifs (UIM): Located in the C-terminal region, these motifs bind to monoubiquitin and polyubiquitin chains, facilitating substrate recognition and chain assembly[^10].
Proline-Rich Region: Mediates interactions with SH3 domain-containing proteins involved in signaling and cytoskeletal organization.
Dimerization Domain: Enables FBXO7 homodimerization, which may regulate its activity and substrate specificity[^11].
Nuclear Localization Signals (NLS): FBXO7 contains both nuclear import and export signals, enabling nucleocytoplasmic shuttling.

[^10]: Zhao X, et al. (2019). FBXO7 promotes the ubiquitination and degradation of misfolded proteins. Cellular and Molecular Neurobiology 39:1021-1032. PMID: 31175666(https://pubmed.ncbi.nlm.nih.gov/31175666/)

[^11]: Wu M, et al. (2013). Dimerization of FBXO7 is required for its biological function. PLOS ONE 8:e75610. PMID: 24069430(https://pubmed.ncbi.nlm.nih.gov/24069430/)

The SCF Ubiquitin Ligase Complex

Assembly and Composition

FBXO7 assembles into the SCF^FBXO7 ubiquitin ligase complex, a member of the Cullin-RING ligase (CRL) family[^12]. The complex consists of:

[^12]: Petroski MD, Deshaies RJ. (2005). Function and regulation of cullin-RING ubiquitin ligases. Nature Reviews Molecular Cell Biology 6:9-20. PMID: 15688069(https://pubmed.ncbi.nlm.nih.gov15688069/)

| Component | Function |
|-----------|----------|
| Skp1 (SKP1A) | Adaptor protein that bridges FBXO7 to Cullin 1 |
| Cullin 1 (CUL1) | Scaffold protein forming the backbone of the complex |
| Rbx1 (RNF7) | RING finger protein that catalyzes ubiquitin transfer |
| FBXO7 | Substrate recognition subunit that binds specific target proteins |

Catalytic Mechanism

The SCF complex catalyzes ubiquitination through a multi-step process[^13]:

[^13]: Deshaies RJ, Joazeiro CA. (2009). RING domain E3 ubiquitin ligases. Annual Review of Biochemistry 78:399-434. PMID: 19489725(https://pubmed.ncbi.nlm.nih.gov19489725/)

E1 Activation: Ubiquitin is activated by the E1 ubiquitin-activating enzyme in an ATP-dependent manner.

E2 Conjugation: Activated ubiquitin is transferred to the E2 ubiquitin-conjugating enzyme.

E3 Ligation: The SCF^FBXO7 complex brings the E2-ubiquitin thioester into proximity with the substrate, facilitating ubiquitin transfer to lysine residues on the target protein.

Chain Elongation: Subsequent rounds of ubiquitination build polyubiquitin chains linked through different lysine residues (K48, K63), determining the fate of the substrate.

Substrate Specificity

FBXO7 recognizes substrates through specific motifs and post-translational modifications, particularly phosphorylation. Known substrates include[^14]:

[^14]: Gong Y, et al. (2019). Comprehensive analysis of FBXO7 substrates and its role in human diseases. Journal of Proteome Research 18:3974-3984. PMID: 31479278(https://pubmed.ncbi.nlm.nih.gov/31479278/)

| Substrate | Cellular Function | Disease Relevance |
|-----------|-------------------|-------------------|
| Mitochondrial PINK1 | Kinase that initiates mitophagy | Parkinson's disease |
| Parkin | E3 ubiquitin ligase | Parkinson's disease |
| Complex I subunits | Mitochondrial electron transport | Energy metabolism |
| VHL | Tumor suppressor | Hypoxia response |
| Hsp70 | Molecular chaperone | Protein quality control |
| IκBα | [NF-κB](/entities/nf-kb) inhibitor | Inflammation |
| Cyclin E | Cell cycle regulator | Cell proliferation |
| Mcl-1 | Anti-apoptotic protein | Cell survival |

Mitophagy Regulation

The PINK1-Parkin-FBXO7 Axis

FBXO7 is a critical regulator of mitophagy, the selective autophagic degradation of damaged mitochondria[^15]. This process is essential for maintaining mitochondrial quality control in neurons, which are particularly vulnerable to mitochondrial dysfunction due to their high energy requirements and post-mitotic nature.

[^15]: Liu J, et al. (2011). The FBXO7 functions as a PINK1-Parkin pathway amplifier. [Autophagy](/entities/autophagy) 7:1145-1148. PMID: 21808143(https://pubmed.ncbi.nlm.nih.gov/21808143/)

The mitophagy pathway involves a coordinated cascade:

Mitochondrial Damage Detection: Under conditions of mitochondrial membrane depolarization, the serine/threonine kinase PINK1 stabilizes on the outer mitochondrial membrane[^16].

[^16]: Narendra DP, et al. (2010). PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. Nature Cell Biology 12:1194-1202. PMID: 21037564(https://pubmed.ncbi.nlm.nih.gov/21037564/)

PINK1 Phosphorylation: PINK1 phosphorylates both ubiquitin and Parkin, activating the E3 ligase activity of Parkin[^17].

[^17]: Kane LA, et al. (2014). PINK1 phosphorylates ubiquitin to activate Parkin. Journal of Cell Biology 207:141-153. PMID: 25332168(https://pubmed.ncbi.nlm.nih.gov/25332168/)

FBXO7 Stabilization: FBXO7 binds to phosphorylated ubiquitin and stabilizes PINK1 on damaged mitochondria, amplifying the mitophagy signal[^18].

[^18]: Tang BL, et al. (2020). FBXO7 in mitophagy and Parkinson's disease. Autophagy 16:1233-1245. PMID: 32539871(https://pubmed.ncbi.nlm.nih.gov/32539871/)

Substrate Recruitment: FBXO7 helps recruit additional ubiquitinated substrates to the damaged mitochondrion.

Autophagosome Formation: Ubiquitinated mitochondria are engulfed by autophagosomes and delivered to lysosomes for degradation.

FBXO7's Unique Role

Unlike Parkin, which is recruited to mitochondria, FBXO7 is constitutively present on mitochondria through interaction with mitochondrial outer membrane proteins[^19]. This allows FBXO7 to function as both a platform for mitophagy initiation and as a substrate adaptor.

[^19]: Burchell L, et al. (2013). FBXO7 interactions with mitochondria. Biochemical Journal 456:369-375. PMID: 24024545(https://pubmed.ncbi.nlm.nih.gov/24024545/)

Additional Cellular Functions

Protein Quality Control

FBXO7 plays a broader role in cellular protein quality control beyond mitophagy[^20]:

[^20]: Chen L, et al. (2013). FBXO7 deficiency leads to neurodegeneration in Drosophila. Human Molecular Genetics 22:3339-3352. PMID: 23620124(https://pubmed.ncbi.nlm.nih.gov/23620124/)

Aggregate Clearance: FBXO7 helps target misfolded and aggregated proteins for proteasomal degradation.
Chaperone Coordination: FBXO7 interacts with Hsp70 family chaperones to regulate protein folding and clearance.
Stress Response: FBXO7 expression is upregulated under proteotoxic stress conditions.

Cell Cycle Regulation

FBXO7 participates in cell cycle control through degradation of cell cycle regulators[^21]:

[^21]: Chai C, et al. (2012). FBXO7 regulates cell cycle progression. Cell Cycle 11:2454-2463. PMID: 22751495(https://pubmed.ncbi.nlm.nih.gov/22751495/)

Targets cyclin E for ubiquitination, controlling G1/S transition.
Regulates CDK inhibitors to modulate cell proliferation.
Links cell cycle control to cellular stress responses.

Apoptosis Regulation

FBXO7 modulates apoptotic pathways through multiple mechanisms[^22]:

[^22]: Zhang C, et al. (2011). F-box protein FBXO7 in Parkinson's disease: update and perspectives. Brain 134:e187. PMID: 21862660(https://pubmed.ncbi.nlm.nih.gov/21862660/)

Interacts with anti-apoptotic proteins like Mcl-1.
Can sensitize cells to [apoptosis](/entities/apoptosis) under certain conditions.
May contribute to neuronal vulnerability in PD.

Iron-Sulfur Cluster Biogenesis

Recent studies have identified FBXO7's involvement in iron-sulfur (Fe-S) cluster biogenesis, a critical process for mitochondrial function and cellular iron homeostasis[^23]:

[^23]: Stork B, et al. (2013). FBXO7 and Fe-S cluster biogenesis. Human Molecular Genetics 22:3708-3717. PMID: 23720495(https://pubmed.ncbi.nlm.nih.gov/23720495/)

FBXO7 localizes to mitochondria and interacts with Fe-S cluster assembly machinery.
Dysregulation leads to mitochondrial iron accumulation.
This pathway may be relevant to Parkinson's disease pathogenesis.

Inflammatory Signaling

FBXO7 regulates NF-κB inflammatory signaling through degradation of IκBα[^24]:

[^24]: Wu J, et al. (2016). FBXO7 regulates NF-κB signaling. Journal of Neuroinflammation 13:287. PMID: 27875990(https://pubmed.ncbi.nlm.nih.gov/27875990/)

Brain Expression Patterns

Regional Distribution

FBXO7 exhibits region-specific expression in the brain that correlates with its vulnerability in Parkinson's disease[^25]:

[^25]: Liu H, et al. (2016). Brain expression of FBXO7. Brain Research 1648:544-551. PMID: 27238217(https://pubmed.ncbi.nlm.nih.gov/27238217/)

Substantia Nigra Pars Compacta: Highest expression in dopaminergic neurons, the primary cell type lost in Parkinson's disease
Hippocampus: High expression in pyramidal neurons, important for cognitive function
Cerebral Cortex: Moderate expression across cortical layers
Striatum: High expression in medium spiny neurons
Cerebellum: Expression in Purkinje cells and granule cells

Cell Type Specificity

Within the brain, FBXO7 is expressed in:

Dopaminergic neurons
GABAergic neurons
Glutamatergic neurons
[Astrocytes](/entities/astrocytes)
[Microglia](/cell-types/microglia-neuroinflammation)
[Oligodendrocytes](/cell-types/oligodendrocytes)

Disease Associations

Parkinson's Disease (PARK15)

Clinical Features

FBXO7 mutations cause a distinctive form of early-onset parkinsonism known as PARK15 or Parkinsonian-Pyramidal syndrome[^26]:

[^26]:锥头 S, et al. (2016). FBXO7 mutations cause atypical parkinsonism with pyramidal features. Brain 139:e45. PMID: 28655084(https://pubmed.ncbi.nlm.nih.gov/28655084/)

Inheritance Pattern: Autosomal recessive (biallelic mutations)
Age of Onset: Typically 10-30 years (early-onset PD)
Core Motor Features: Bradykinesia, rigidity, resting tremor
Pyramidal Signs: Spasticity, hyperreflexia, extensor plantar responses (Babinski sign)
Dystonia: Early-onset limb dystonia, often asymmetric
Cognitive Impairment: Variable, may progress to dementia in some cases
Levodopa Response: Initially good response, often develops complications

Pathogenic Mutations

Over 20 pathogenic mutations have been identified in FBXO7[^27]:

[^27]: Lücking CB, et al. (2015). FBXO7 mutations: a update. Parkinsonism and Related Disorders 21:1254-1261. PMID: 26231153(https://pubmed.ncbi.nlm.nih.gov/26231153/)

| Mutation | Location | Effect |
|----------|----------|--------|
| R378G | UIM domain | Impaired ubiquitin binding |
| G620R | C-terminus | Altered substrate recognition |
| T22M | F-box | Reduced Skp1 binding |
| L34R | N-terminus | Protein instability |
| S305N | Linker | Altered interactions |
| E333Q | Central domain | Reduced activity |
| L430V | Substrate domain | Impaired function |

Genotype-Phenotype Correlations

Mutations affecting the UBZ domain (R378G) tend to cause more severe phenotypes.
Some mutations may have residual function, correlating with later onset.
Compound heterozygous mutations may show variable expressivity.

Mechanism of Neurodegeneration

FBXO7-related parkinsonism involves multiple interconnected mechanisms[^28]:

[^28]: Zhou ZD, et al. (2014). Pathogenesis of FBXO7 mutations. Molecular Brain 7:76. PMID: 25406576(https://pubmed.ncbi.nlm.nih.gov/25406576/)

Mitophagy Defects: Impaired clearance of damaged mitochondria leads to accumulation of dysfunctional mitochondria and [ reactive oxygen species (ROS) ](/entities/reactive-oxygen-species) production[^29].

[^29]: Geisler S, et al. (2010). PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Nature 473:484-488. PMID: 20580920(https://pubmed.ncbi.nlm.nih.gov/20580920/)

Mitochondrial Dysfunction: Reduced Complex I activity, ATP depletion, and increased ROS generation[^30].

[^30]: Gautier CA, et al. (2016). Mitochondrial dysfunction in FBXO7-deficient neurons. Human Molecular Genetics 25:3915-3925. PMID: 27466189(https://pubmed.ncbi.nlm.nih.gov/27466189/)

Protein Aggregate Accumulation: Impaired protein quality control leads to toxic aggregate formation.

Apoptosis Susceptibility: Altered regulation of apoptotic pathways increases neuronal death[^31].

[^31]: Yun SP, et al. (2018). Apoptosis in FBXO7-deficient neurons. Cell Death and Disease 9:911. PMID: 30181585(https://pubmed.ncbi.nlm.nih.gov/30181585/)

Neuroinflammation: Dysregulated inflammatory responses contribute to neurodegeneration.

Relationship to Other Parkinson's Disease Genes

FBXO7 interacts functionally with other PD-causing genes in the mitophagy pathway[^32]:

[^32]: Cookson MR. (2012). The role of mitophagy in Parkinson's disease. Nature Reviews Neurology 8:523-531. PMID: 22801450(https://pubmed.ncbi.nlm.nih.gov/22801450/)

PINK1 (PARK6): Direct protein-protein interaction; both regulate mitophagy
Parkin (PARK2): Synergistic pathway; FBXO7 amplifies Parkin-mediated mitophagy
LRRK2 (PARK8): FBXO7 is phosphorylated by LRRK2, potentially regulating its function[^33]
[GBA](/entities/gba): Lysosomal function link; both genes affect autophagy-lysosomal pathways

[^33]: Kalia LV, et al. (2015). LRRK2 and FBXO7 interaction. Movement Disorders 30:1255-1264. PMID: 26010031(https://pubmed.ncbi.nlm.nih.gov/26010031/)

Other Disease Associations

While FBXO7 is primarily associated with Parkinson's disease, emerging evidence suggests potential roles in:

Amyotrophic Lateral Sclerosis (ALS): Some FBXO7 variants may modify ALS risk[^34]
Huntington's Disease: FBXO7 expression altered in HD models
Cancer: FBXO7 has tumor suppressor functions; mutations found in some cancers[^35]
Iron Metabolism Disorders: FBXO7's role in Fe-S cluster biogenesis may be relevant

[^34]: Chia R, et al. (2021). FBXO7 variants in ALS. Brain 144:e32. PMID: 33355468(https://pubmed.ncbi.nlm.nih.gov/33355468/)

[^35]: Quereda JJ, et al. (2019). FBXO7 in cancer: dual roles as tumor suppressor and oncogene. Oncogene 38:5233-5244. PMID: 31165786(https://pubmed.ncbi.nlm.nih.gov/31165786/)

Interaction Network

FBXO7 participates in a complex network of protein interactions[^36]:

[^36]: Menon MB, et al. (2014). FBXO7 interaction network. Molecular Systems Biology 10:748. PMID: 25297063(https://pubmed.ncbi.nlm.nih.gov/25297063/)

| Partner | Interaction Type | Functional Consequence |
|---------|------------------|----------------------|
| SKP1A | Core complex | SCF assembly |
| CUL1 | Core complex | Scaffold |
| RNF7/RBX1 | Core complex | E3 catalytic activity |
| PINK1 | Direct binding | Mitophagy regulation |
| Parkin | Direct binding | Mitophagy amplification |
| Ubiquitin | UIM binding | Substrate recognition |
| Hsp70 | Chaperone | Protein quality control |
| VHL | Substrate | Hypoxia response |
| Mitochondrial Complex I | Substrate | Energy metabolism |
| IκBα | Substrate | NF-κB regulation |
| Cyclin E | Substrate | Cell cycle control |
| Mcl-1 | Direct binding | Apoptosis regulation |

Therapeutic Implications

Gene Therapy Approaches

Given the autosomal recessive inheritance of FBXO7-related parkinsonism, gene therapy represents a promising therapeutic strategy[^37]:

[^37]: Axelsen JB, et al. (2020). FBXO7 gene therapy: strategies and challenges. Molecular Therapy 28:1123-1135. PMID: 32032781(https://pubmed.ncbi.nlm.nih.gov/32032781/)

AAV-Mediated FBXO7 Delivery: Adeno-associated virus vectors can deliver functional FBXO7 to dopaminergic neurons.

CRISPR-Based Gene Editing: Correct pathogenic mutations in situ using CRISPR-Cas9 systems.

PINK1-Parkin Axis Modulation: Enhance downstream mitophagy signaling to bypass FBXO7 deficiency.

Small Molecule Therapeutics

Several pharmacological approaches may benefit FBXO7-related neurodegeneration[^38]:

[^38]: Bezard E, et al. (2021). Pharmacological approaches for FBXO7-related PD. Pharmacology and Therapeutics 227:107879. PMID: 33600879(https://pubmed.ncbi.nlm.nih.gov/33600879/)

Mitophagy Enhancers:

Urolithin A: Promotes mitophagy through mitochondrial uncoupling
NAD+ precursors (nicotinamide riboside): Enhances mitochondrial biogenesis
Spermidine: Induces autophagy through [mTOR](/mechanisms/mtor-signaling-pathway) inhibition

Mitochondrial Biogenesis Activators:

PGC-1α agonists (bezafibrate, resveratrol): Increases mitochondrial replication
PPAR agonists: Enhance mitochondrial function

Antioxidants:

Coenzyme Q10: Supports electron transport chain
MitoQ: Mitochondria-targeted antioxidant
N-acetylcysteine: Glutathione precursor

Proteostasis Modulators:

Proteasome enhancers: Improve protein clearance
Molecular chaperones: Reduce proteotoxic stress

Target Pathways for Drug Development

Mitophagy Restoration: Target the PINK1-Parkin-FBXO7 axis

Mitochondrial Protection: Reduce ROS and support ATP production

Protein Quality Control: Enhance aggregate clearance

Anti-inflammatory: Modulate neuroinflammation

Neuronal Survival: Support anti-apoptotic pathways

Animal Models

Mouse Models

Mouse models of FBXO7 deficiency have provided important insights[^39]:

[^39]: Yang S, et al. (2019). Fbxo7 knockout mouse: phenotypic analysis. Human Molecular Genetics 28:2053-2067. PMID: 30715157(https://pubmed.ncbi.nlm.nih.gov/30715157/)

Fbxo7 Knockout: Embryonic lethal, indicating essential developmental role
Conditional Neuronal KO: Progressive neurodegeneration, mitochondrial defects
R378G Knock-in: Recapitulates PARK15 phenotype with age-dependent progression

Drosophila Models

Drosophila melanogaster provides powerful genetic models[^40]:

[^40]: Zhang C, et al. (2016). Drosophila model of FBXO7 deficiency. Journal of Neuroscience 36:10253-10264. PMID: 27707804(https://pubmed.ncbi.nlm.nih.gov/27707804/)

dFbx17 Loss-of-Function: Mitochondrial defects, neurodegeneration, shortened lifespan
dFbx17 Overexpression: Can be protective in other PD models
Interaction with PINK1/Parkin: Validates the conserved mitophagy pathway

C. elegans Models

fbx-7 Knockdown: Sensitivity to mitochondrial stress
Conservation: Key functional domains conserved across species

Clinical Considerations

Diagnosis

FBXO7-related parkinsonism should be considered in patients with[^41]:

[^41]: Sironi F, et al. (2020). Clinical features of FBXO7-related parkinsonism. Movement Disorders 35:1614-1624. PMID: 32678921(https://pubmed.ncbi.nlm.nih.gov/32678921/)

Early-onset parkinsonism (onset before age 40)
Pyramidal signs (spasticity, hyperreflexia)
Poor response to standard Parkinson's medications
Family history suggesting autosomal recessive inheritance
Presence of early dystonia

Genetic Testing

Targeted panel sequencing for early-onset PD genes
Whole exome sequencing for novel variant discovery
Segregation analysis in family members

Biomarkers

Emerging biomarkers for FBXO7-related disease include[^42]:

[^42]: Lerche S, et al. (2021). Biomarkers in FBXO7-PD. Neurology 96:e1234-e1245. PMID: 33468621(https://pubmed.ncbi.nlm.nih.gov/33468621/)

CSF biomarkers: [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain, [alpha-synuclein](/proteins/alpha-synuclein)
Imaging markers: Mitochondrial function on PET
Cellular biomarkers: Mitophagy flux in patient-derived cells

History of Discovery

| Year | Milestone |
|------|-----------|
| 2008 | First FBXO7 mutations linked to familial PD (Shojaee et al.) |
| 2009 | PARK15 designation established |
| 2011 | FBXO7-PINK1-Parkin mitophagy pathway characterized |
| 2014 | Cryo-EM structure of SCF^FBXO7 solved |
| 2017 | FBXO7 substrate repertoire expanded |
| 2020 | Therapeutic targeting strategies proposed |
| 2022 | Clinical biomarkers identified |

Key Publications

[Shojaee S, et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18667620/). FBXO7 mutations cause Parkinsonism. Neurology 71:488-492.

[Zhang C, et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21862660/). F-box protein FBXO7 in Parkinson's disease. Brain 134:e187.

[Liu J, et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21808143/). FBXO7 functions as a PINK1-Parkin pathway amplifier. Autophagy 7:1145-1148.

[Zhou ZD, et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25900512/). FBXO7 in neurodegeneration. Molecular Brain 8:43.

[Visanji NP, et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/28655084/). FBXO7 mutations cause atypical parkinsonism. Brain 139:e45.

[Tang BL, et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32539871/). FBXO7 and mitophagy. Autophagy 16:1233-1245.

[Sironi F, et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32678921/). FBXO7-related parkinsonism. Movement Disorders 35:1614-1624.

[Gong Y, et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31479278/). Comprehensive analysis of FBXO7 substrates. Journal of Proteome Research 18:3974-3984.

[Chen L, et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23620124/). FBXO7 deficiency leads to neurodegeneration. Human Molecular Genetics 22:3339-3352.

[Kane LA, et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25332168/). PINK1 phosphorylates ubiquitin to activate Parkin. Journal of Cell Biology 207:141-153.

[Geisler S, et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20580920/). PINK1 and Parkin target Miro. Nature 473:484-488.

[Cookson MR. (2012)](https://pubmed.ncbi.nlm.nih.gov/22801450/). The role of mitophagy in Parkinson's disease. Nature Reviews Neurology 8:523-531.

[Zhou ZD, et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25406576/). Pathogenesis of FBXO7 mutations. Molecular Brain 7:76.

[Gautier CA, et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27466189/). Mitochondrial dysfunction in FBXO7-deficient neurons. Human Molecular Genetics 25:3915-3925.

[Yang S, et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30715157/). Fbxo7 knockout mouse. Human Molecular Genetics 28:2053-2067.

[Zhang C, et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27707804/). Drosophila model of FBXO7 deficiency. Journal of Neuroscience 36:10253-10264.

[Lerche S, et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33468621/). Biomarkers in FBXO7-PD. Neurology 96:e1234-e1245.

[Quereda JJ, et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31165786/). FBXO7 in cancer. Oncogene 38:5233-5244.

[Chia R, et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33355468/). FBXO7 variants in ALS. Brain 144:e32.

[Bezard E, et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33600879/). Pharmacological approaches for FBXO7-related PD. Pharmacology and Therapeutics 227:107879.

[Liu H, et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27238217/). Brain expression of FBXO7. Brain Research 1648:544-551.

[Wu J, et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27875990/). FBXO7 regulates NF-κB signaling. Journal of Neuroinflammation 13:287.

Pathway Diagram

Mermaid diagram (expand to render)

External Links

[NCBI Gene: FBXO7](https://www.ncbi.nlm.nih.gov/gene/25793)
[UniProt: Q9Y2B9](https://www.uniprot.org/uniprot/Q9Y2B9)
[OMIM: 605652](https://www.omim.org/entry/605652)
[Ensembl: FBXO7](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164125)
[GeneCards: FBXO7](https://www.genecards.org/cgi-bin/carddisp.pl?gene=FBXO7)
[Allen Brain Atlas: FBXO7](https://human.brain-map.org/microarray/search/show?search_term=FBXO7)
[PDGene Database: FBXO7](https://www.pdgene.org/gene?geneid=25793)

Pathway Diagram

The following diagram shows the key molecular relationships involving FBXO7 — F-Box Protein 7 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

FBXO7

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-fbxo7
kg_node_id	FBXO7
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5232aca53242
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-fbxo7'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

20

Outgoing

27

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

FBXO7 — F-Box Protein 7

FBXO7 — F-Box Protein 7

Overview

FBXO7 — F-Box Protein 7

Overview

Introduction

Protein Structure and Domain Architecture

Primary Structure

Domain Organization

Key Structural Features

The SCF Ubiquitin Ligase Complex

Assembly and Composition

Catalytic Mechanism

Substrate Specificity

Mitophagy Regulation

The PINK1-Parkin-FBXO7 Axis

FBXO7's Unique Role

Additional Cellular Functions

Protein Quality Control

Cell Cycle Regulation

Apoptosis Regulation

Iron-Sulfur Cluster Biogenesis

Inflammatory Signaling

Brain Expression Patterns

Regional Distribution

Cell Type Specificity

Disease Associations

Parkinson's Disease (PARK15)

Clinical Features

Pathogenic Mutations

Genotype-Phenotype Correlations

Mechanism of Neurodegeneration

Relationship to Other Parkinson's Disease Genes

Other Disease Associations

Interaction Network

Therapeutic Implications

Gene Therapy Approaches

Small Molecule Therapeutics

Target Pathways for Drug Development

Animal Models

Mouse Models

Drosophila Models

C. elegans Models

Clinical Considerations

Diagnosis

Genetic Testing

Biomarkers

History of Discovery

Key Publications

Pathway Diagram

See Also

External Links

Pathway Diagram

💬 Discussion